Clinical Trials Logo

Solid Tumor clinical trials

View clinical trials related to Solid Tumor.

Filter by:

NCT ID: NCT02793466 Completed - Lymphoma Clinical Trials

Durvalumab in Pediatric and Adolescent Patients

Start date: July 2016
Phase: Phase 1
Study type: Interventional

This clinical trial is the first clinical trial to study Durvalumab, a checkpoint inhibitor which stimulates the patient's own immune system to act against cancer cells in children and adolescents. This trial will assess the safety and tolerability of Durvalumab in children and adolescents and also study how Durvalumab is processed in their bodies.

NCT ID: NCT02784795 Completed - Breast Cancer Clinical Trials

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Start date: November 4, 2016
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.

NCT ID: NCT02742935 Completed - Breast Cancer Clinical Trials

A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects

Start date: April 27, 2016
Phase: Phase 1
Study type: Interventional

This is an open-label, non-randomized, dose escalation phase I trial to evaluate safety and tolerability of SHR-1210 in patients with advanced solid tumors. The primary objective is to assess safety and tolerability of SHR-1210 and identify recommended phase II doses of SHR-1210 in patients with advanced solid tumors.

NCT ID: NCT02730481 Completed - Solid Tumor Clinical Trials

A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies

Start date: March 2016
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, safety study. Eligible subjects will be adults with advanced malignancies. The study includes a pretreatment and treatment phase. The pretreatment phase consists of screening and baseline periods. The treatment phase consists of 4-week treatment periods and a follow-up period.

NCT ID: NCT02718911 Completed - Solid Tumor Clinical Trials

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

Start date: June 16, 2016
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety of the colony-stimulating factor 1 receptor (CSF-1R) inhibitor LY3022855 in combination with durvalumab or tremelimumab in participants with advanced solid tumors.

NCT ID: NCT02715531 Completed - Solid Tumor Clinical Trials

A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors

Start date: April 6, 2016
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab in combination with bevacizumab, bevacizumab + oxaliplatin, leucovorin and 5-fluorouracil (5-FU) (FOLFOX), vanucizumab, nab-paclitaxel + gemcitabine, FOLFOX, or 5-FU + cisplatin, in participants with solid tumors.

NCT ID: NCT02705105 Completed - Cancer Clinical Trials

Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors

Start date: February 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) or the recommended fixed dose of the combinations of mogamulizumab and nivolumab in subjects with locally advanced or metastatic solid tumors.

NCT ID: NCT02648425 Completed - Solid Tumor Clinical Trials

Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine

Start date: August 5, 2014
Phase: Phase 1
Study type: Interventional

This is a phase IB study to assess the safety and tolerability of ASLAN001 when given in combination with either Cisplatin and 5-Fluorouracil or Cisplatin and Capecitabine, with a view to identifying the recommended Phase II dose.

NCT ID: NCT02643303 Completed - Breast Cancer Clinical Trials

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Start date: December 28, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multicenter, Phase 1/2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment (TME) modulator poly-ICLC, a TLR3 agonist, in subjects with advanced, measurable, biopsy-accessible cancers.

NCT ID: NCT02640508 Completed - Cancer Clinical Trials

Eribulin and Lenvatinib in Advanced Solid Tumors

Start date: May 2016
Phase: Phase 2
Study type: Interventional

The overall purpose of this study is to determine the overall response rate, efficacy and safety of the combination of eribulin and Lenvatinib.